Definitive Contract 75N93022C00042
Award Date
9/1/22
Potential Completion Date
8/25/25
Potential Value
$1.5M
Federal Agency
National Institute of Allergy and Infectious Diseases
Awardee
Hbvtech, L.l.c
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Cost Plus Fixed Fee
Place of Performance
Germantown, MD, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
1
Legislative Mandate
Employment Eligibility Verification
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This SBIR Phase I contract from the National Institutes of Health's National Institute of Allergy and Infectious Diseases, valued at $299,868, was awarded to Hbvtech of Germantown, Maryland. The contract supports research outlined in Topic 084 of the solicitation, which sought proposals for antiviral drugs to cure chronic hepatitis B virus infection. The firm-fixed price contract is a total small business set-aside running from August 2020 through October 2021. The award advances the NIH/NIAID's...
This definitive contract was awarded by the National Institutes of Health National Institute of Allergy and Infectious Diseases to Casterbridge Pharmaceuticals, Inc. of Woburn, Massachusetts. The $297,245 firm fixed price contract is for research under Phase I of the Small Business Innovation Research program's Topic 084 entitled "Antiviral Drugs to Cure Chronic Hepatitis B Virus Infection." The place of performance is the prime contractor's facility in Woburn. The period of...
The Department of Health and Human Services National Institutes of Health National Institute of Allergy and Infectious Diseases awarded a $300,000 firm fixed price definitive contract to Zymeron Corporation under SBIR PHS 2020-1 Topic 084. This Small Business Innovation Research Phase I contract supports research and development of antiviral drugs to cure chronic hepatitis B virus infection. The solicitation sought proposals for Phase I and Phase II SBIR contracts to advance the missions of...
This definitive contract from the Department of Health and Human Services' National Institutes of Health's National Institute of Allergy and Infectious Diseases (HHS-NIH-NIAID) awards Regulus Therapeutics Inc. $300,000 under the SBIR PHS 2020-1 Topic 084 solicitation. The solicitation sought proposals to conduct research and development in support of developing antiviral drugs to cure chronic hepatitis B virus infection. This is a firm fixed price, total small business set-aside contract to be...
<p>This is a $299,961.00 SBIR Phase I contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency, to Cubit Diagnostics, Inc. (doing business as Arete Biosciences) for the development of an ultrasensitive, rapid, and easy-to-use at-home molecular test for Hepatitis C, Hepatitis B, and HIV. The contract has a firm fixed price and a completion date of April 30, 2025. It is designated as a Total Small Business set-aside contract.</p>
The Department of Health and Human Services National Institutes of Health National Institute of Allergy and Infectious Diseases awarded a $2M definitive contract to Accelevir Diagnostics LLC of East Case, MD. The contract is for ProViral Sequencing Driven Development of EnHanced IPDAV2 with Global HIV-1 Group M Coverage to Support Worldwide Cure and Clinical Trials. The prime contractor will perform research and development of enhanced diagnostics to support global HIV cure and clinical trials...
This federal contract award was issued by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to the International AIDS Vaccine Initiative (IAVI), a global non-profit organization focused on HIV vaccine development. The $1,098,404.00 cost-plus-fixed-fee contract provides funding for IAVI to perform cell line optimization and pre-master bank generation for SB 301, a vaccine candidate for hepatitis B virus (HBV). This work is being...
This is a $300,000 Firm Fixed Price contract awarded by the Department of Health and Human Services' National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases to Vitruvian Bio, LLC, a small disadvantaged woman-owned business. The contract is for a Small Business Innovation Research (SBIR) Phase I project to be completed by June 30, 2023. The award is associated with a larger SBIR solicitation that sought innovative research proposals from small businesses to...
This is a $1,500,000.00 Small Business Innovation Research (SBIR) Phase II contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a division of the Department of Health and Human Services, to Cure Systems LLC, a self-certified small disadvantaged business located in Newton, Massachusetts. The contract is for the research and development of "Vector-Based Delivery of HIV Broadly Neutralizing Antibodies," a specialized approach to developing advanced...
The Department of Health and Human Services National Institutes of Health National Institute of Allergy and Infectious Diseases awarded a Firm Fixed Price Definitive Contract to CFD Research Corporation, a for-profit organization, to perform Phase I SBIR research on a "SMART BIOREACTOR FOR LARGE-SCALE HIGH TITER PHAGE PREPS" project. The contract has a potential value of $299,946.26 and a completion date of August 15, 2022. This SBIR award was not set aside for a specific business...